Show results for
cancer-center-celebrates-2-000-patients Downloads
10 downloads found
Junction Adhesion Molecule C (JAM-C) has been studied at the laboratories of Prof. Beat Imhof and Prof. Thomas Matthes at the Université de Genève for over 10+ years (36 peer reviewed publications). There is in addition 60+ publications from other laboratories. JAM-C is expressed by certain lymphocytes and prominently localises to tight junctions of endotelial cells. In many ...
ByAbologix
Olfactomedin-like protein 3 (Olfml3) creates an angiogenic environment in tumours and is associated with vascular growth factors BMP-4 and PDGF. Olfml3 is overexpressed in some cancers. Blocking Olfml3 with highly specific monoclonal antibodies is therefore a logical scientific approach in order to develop new generation inhibitors of angiogenesis. Abologix has produced several recombinant ...
ByAbologix
It is our goal to help you deliver the best possible radiotherapy, for every patient, every time. Designed in collaboration with industry-leading experts and world-renowned cancer research institutions, Elekta Unity—our breakthrough MR-Linac technology— positions you at the forefront of patient-centric cancer ...
A tool that performs in silico clinical trials to assess the neutropenic effects of a chemotherapeutic agent in a virtual population of cancer patients ...
PCa GnRH Agonists Simulator enables simulations of clinical trials on a virtual population of prostate cancer patients being treated with a GnRH agonist ...
OncoSELECT: Smart liquid biopsy panels with selected key genes per tumor type. The Liquid Biopsy Solution For Disease Monitoring Or Therapeutic Decision. OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for lung (NSCLC), colorectal and breast (HR+ or HER2+) cancer patients. It is the perfect solution to identify therapeutic options for cancer ...
To date, the classification of cancers has been based solely on the phenotypic and genotypic characteristics of tumor cells. A new paradigm, scientifically well established and recommended by WHO guidelines, relies on the introduction of the immune response as a new prognostic parameter to predict and refine the clinical outcomes of cancer patients. Maximize patient survival rates with an ...
ByVeracyte
Use our immune-oncology IVD solutions IMMUNOSCORE in Localized Colon Cancer and IMMUNOSCORE IC in Non-Small Cell Lung Cancer to improve patient care management with immune contexture ...
ByVeracyte
Our flagship product—the Intraop® Mobetron®—is used by the leading cancer physicians in the best hospitals, clinics and academic centers in the world. The Mobetron is the first mobile, self-shielded electron-beam linear accelerator (LINAC) machine designed to deliver Intraoperative Radiation Therapy (IORT) to cancer patients during surgery. This innovation brings safe, ...
Providing risk-assessment for hereditary cancer syndromes for patients and their families. xG+ (extended hereditary cancers): Covers genes associated with multiple hereditary cancer types, including common hereditary cancers (breast, ovarian, colorectal, endometrial, prostate, pancreatic) and others (renal/urinary tract, gastric, melanoma, thyroid, endocrine, sarcomas, central nervous system, ...
ByTempus